Accord Logo

Intended for UK patients and members of the public

Irbesartan Accord 300mg Film-coated Tablets

Discontinued Other versions of this medicine may still be available. Information for reference purposes.

Irbesartan Accord 300mg Film-coated Tablets

PL Number:
20075/0354
MA Holder:
Accord Healthcare Limited
Product Classification:
POM
Product Status:
Discontinued

Product Documentation

  • Description of update: To update sections 4.1, 4.2, 4.4, 5.1, 5.3 of the SmPC and sections 2, 3 of the leaflet in-line with information of reference product (Aprovel 75mg, 150 mg and 300 mg tablets; MAH: Sanofi Winthrop Industrie, France; EU procedure number: EMEA/H/C/000141). Additionally, applicant has updated sections 2, 3, 4.3, 4.5, 4.6, 4.8, 4.9, 5.2 of the SmPC and sections 1, 4, 5 and 6 of the leaflet with editorial changes.

    Date of approval: 01/10/2026

    SmPC sections updated: 2, 3, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.1, 5.2, 5.3 and 10

  • Description of update: To update sections 4.1, 4.2, 4.4, 5.1, 5.3 of the SmPC and sections 2, 3 of the leaflet in-line with information of reference product (Aprovel 75mg, 150 mg and 300 mg tablets; MAH: Sanofi Winthrop Industrie, France; EU procedure number: EMEA/H/C/000141). Additionally, applicant has updated sections 2, 3, 4.3, 4.5, 4.6, 4.8, 4.9, 5.2 of the SmPC and sections 1, 4, 5 and 6 of the leaflet with editorial changes.

    Date of approval: 01/10/2026

    PIL sections updated: 1, 2, 3, 4, 5 and 6

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.

Report a side effect or a product complaint

For any further assistance, please get in touch.

View product information as a: